Renal cell carcinoma (RCC) will cause greater than 12 000 deaths in the United States this year. The lack of effective therapy for disseminated RCC has stimulated the search for novel treatments including immunotherapeutic strategies, but poor therapeutic responses and marked toxicity have limited their use. The tumor necrosis factor (TNF) family member TNF-related apoptosisinducing ligand (TRAIL)/Apo-2L induces apoptosis in various tumor cell types, while having little cytotoxicity against normal cells. In this study, we investigated the tumoricidal potential of a recombinant adenovirus encoding human TNFSF10 (Ad5-TRAIL), alone and in combination with a panel of histone deacetylase inhibitors (HDACi), against the TRAIL/Apo-2L-resistant RCC line 786-O and normal human renal proximal tubule epithelial cells (RPTEC). Ad5-TRAIL was unable to induce apoptosis in either 786-O or RPTEC alone; however, tumor cell apoptosis occurred when Ad5-TRAIL was combined with HDAC inhibition. Except when combined with trichostatin A, RPTEC were not sensitized to Ad5-TRAIL by HDACi. In 786-O, HDAC inhibition induced CAR expression, permitting increased adenoviral infection and transgene expression. It also induced TRAIL-R2 expression, accelerated the deathinducing signaling complex formation and enhanced caspase-8 activation. Our results demonstrate the utility of combining Ad5-TRAIL with HDACi against RCC, and mechanistically define how this combination modulates RCC sensitivity to TRAIL/Apo-2L and adenoviral infection.
Introduction
Although many agents induce apoptotic death, the deathinducing receptors of the tumor necrosis factor (TNF) receptor family and their cognate TNF family ligands have garnered the most interest because of their role in numerous physiological events and potential therapeutic function. One member of the TNF family, TNF-related apoptosis-inducing ligand (TRAIL), has been intensely studied because early analyses demonstrated that recombinant, soluble TRAIL possessed the unique ability of inducing apoptosis in a broad range of tumor cell lines, while having little to no activity against normal cells.
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Based on these results, it was suggested that TRAIL could be used as an antitumor therapy without the toxic side effects seen with other TNF family members, namely FasL and TNF. As an alternative to soluble TRAIL, we were the first to report the development of a recombinant adenoviral vector encoding human TNFSF10 (Ad5-TRAIL) that permitted delivery of the gene directly into tumors, 4, 5 and this approach has since been exploited by others. 6, 7 The use of TNFSF10 in a gene transfer therapy setting presents a variety of new possibilities for using TRAIL as an antitumor agent. The present study was undertaken to investigate the combination therapy of Ad5-TRAIL and histone deacetylase inhibitors (HDACi) against human renal cell carcinoma.
Materials and methods

Histone deacetylase inhibitors
Depsipeptide was obtained from the Drug Synthesis & Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, NCI (Bethesda, MD). Trichostatin A and sodium butyrate were purchased from Sigma (St Louis, MO), and MS275 and oxamflatin were purchased from Calbiochem (San Diego, CA).
Cell lines
The human renal cell carcinoma (RCC) cell line 786-O was obtained from ATCC (Rockville, MD), and cultured in RPMI 1640 medium supplemented with 10% fetal calf serum, 1% non-essential amino acids, 1 mM sodium pyruvate and 1% streptomycin/penicillin solution. Normal human renal proximal tubule epithelial cells (RPTEC) were obtained from Cambrex (San Diego, CA).
Production of Ad5-TRAIL
A replication-deficient adenovirus encoding human TNFSF10 (Ad5-TRAIL) 8 expressed from the cytomegalovirus promoter was generated at the University of Iowa Gene Transfer Vector Core (Iowa City, IA) using the RAPAd.I system. 9 Recombinant adenovirus encoding nuclear-targeted bacterial b-galactosidase (Ad5-bgal), produced in the same way, was used as a control.
Ad5-TRAIL-mediated killing
Tumor and normal cell sensitivity to Ad5-TRAIL or Ad5-bgal was assayed by pretreating the cells in 24-well plates (5 Â 10 5 cells/well) with HDACi for 16 h before adding Ad5-TRAIL or Ad5-bgal. Apoptosis was measured after 12 h by staining with FITC-annexin V (R&D Systems, Minneapolis, MN) and propidium iodide (Sigma).
TRAIL ELISA
The level of TRAIL protein in the culture supernatants and tumor cell lysates was quantitated using an ELISA purchased from Diaclone Research (Besancon, France).
Quantitative PCR 786-O cells were plated at 5 Â 10 5 cells/well in 24-well plates, and pretreated for 16 h with HDACi or vehicle control. Cells were then infected with Ad5-bgal for 24 h. Total genomic DNA was harvested using the Qiagen's DNeasy Tissue kit (Valencia, CA). PCR primers (forward: 5 0 -CGCGGGATTGTGACTGACT-3 0 , reverse: 5 0 -GCCA AAAGAGCCGTCAACTT-3 0 ) and probe (5 0 -FAM-AGC AGTGCAGCTTCCCGTTCATCC-TAMRA-3 0 ) amplified the pIX region of type V adenovirus. Real-time PCR analysis was carried out using 50 ng genomic DNA per reaction, and PCR reactions were performed following the Taqman Universal PCR Master Mix protocol (Applied Biosystems, Foster City, CA). All samples were related to the standard curve to determine copy number per 50 ng genomic DNA.
Flow cytometry
Vehicle or HDACi-treated cells were incubated with the PE-conjugated DJR1 (1 mg/ml; eBioscience, San Diego, CA), DJR2-4 (eBioscience), specific for TRAIL-R1 or TRAIL-R2, respectively, or a PE-conjugated mouse IgG1 isotype control mAb (eBioscience) for 1 h at 41C. After washing, cells were analyzed immediately on a FACScan (Becton Dickinson, San Jose, CA).
Immunoprecipitation and Western blot analysis
For TRAIL receptor the death-inducing signaling complex (DISC) immunoprecipitation, 786-O cells (40 Â 10 6 / condition) were first treated with either HDACi or vehicle for 16 h and then incubated with Flag-tagged rTRAIL/ Apo-2L (1 mg/ml; Alexis, San Diego, CA) and biotinylated anti-Flag mAb (M2, 2 mg/ml; Sigma) for 1 h at 371C. Adding 20 volumes of ice-cold PBS stopped incubation with TRAIL/Apo-2L, and cell pellets were lysed by addition of 1 ml lysis buffer per 40 Â 10 6 cells. Protein complexes were precipitated by overnight incubation with 25 ml streptavidin beads. After overnight incubation, beads were washed with lysis buffer and proteins were eluted from the beads by addition of 50 ml 2 Â reducing sample buffer, heated for 5 min at 1001C, separated by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membrane. Western blot detection was performed as follows: nitrocellulose membranes were blocked for 4 h with 5% non-fat dry milk in PBS containing 0.1% Tween 20, followed by overnight incubation with anti-TRAIL-R2 antiserum (Alexis Biochemicals) or anti-Fas-associated death domain (FADD) mAb (BD Transduction Laboratories, San Diego, CA). Membranes were washed and then incubated with peroxidase-conjugated donkey anti-rabbit (diluted 1:1000; Amersham, Piscataway, NJ) or goat anti-mouse IgG (diluted 1:5000; Jackson ImmunoResearch, West Grove, PA) for 1 h. Following several washes, the blots were developed by chemiluminescence according to the manufacturer's protocol (SuperSignal West Pico Chemiluminescence Substrate, Pierce, Rockford, IL).
Caspase activity
/well in a 24-well plate) were treated with HDACi or vehicles for 16 h and then with Ad5-TRAIL (1000 PFU/cell) for 12 h. The cells were harvested and caspase-8 activity was measured using a carboxyfluorescein-labeled leucine-glutamic acid-threonine-aspartic acid fluoromethyl ketone (Immunochemistry Technologies, Bloomington, MN). Briefly, cells were incubated with the 1 Â FLICA solution for 1 h at 371C and then immediately analyzed on a FACScan.
Results and discussion
Histone acetyl transferases and HDACs alter the dynamics of chromatin folding during gene transcription by catalyzing the addition or hydrolysis of acetyl groups from amino-terminal lysine residues of the nucleosomal core histones. 10 Because they possess numerous antiproliferative effects, 8 HDACi are being heavily investigated as anticancer agents. Thus, we treated 786-O with depsipeptide, MS-275, oxamflatin, sodium butyrate and trichostatin A for 16 h, before adding Ad5-TRAIL. After 12 h, apoptotic cell death was measured, and it was observed that oxamflatin, MS-275, sodium butyrate and trichostatin A facilitated the greatest augmentation in tumor cell death (Figure 1a ). This killing was TRAILspecific, as Ad5-bgal did not induce apoptosis with or without HDACi treatment. We also determined if these same HDACi sensitized normal human RPTEC to Ad5-TRAIL. With the exception of trichostatin A, RPTEC remained resistant to Ad5-TRAIL after HDACi pretreatment.
One of the unique characteristics of HDACi is their ability to enhance recombinant adenovirus transgene expression. 11 Thus, we measured Ad5-TRAIL transgene expression after HDACi and Ad5-TRAIL treatment using ELISA 24 h after infection. All HDACi increased Ad5-TRAIL transgene expression, especially at lower 12 Thus, we examined TRAIL-R1 and TRAIL-R2 expression on HDACi-or vehicle-treated 786-O cells. In all cases, HDACi treatment did not alter TRAIL-R1 expression, but TRAIL-R2 levels increased, especially with sodium butyrate and trichostatin A (Figure 1d ). By comparison, normal RPTEC did not demonstrate much alteration in either TRAIL-R1 or TRAIL-R2. These results indicate that not only does HDAC inhibition increase Ad5-TRAIL transgene expression, but it also makes 786-O cells potentially more responsive to TRAIL by increasing TRAIL-R2 expression.
The signaling cascade that is initiated when either TRAIL-R1 or TRAIL-R2 binds to TRAIL requires receptor trimerization and interaction between signaling mediators and the cytoplasmic domain of the TRAIL receptors. 13 The death-inducing signaling complex is formed when FADD and caspase-8 are recruited, and this complex facilitates the autocatalytic cleavage of caspase-8, which then allows for the caspase cascade to be activated and signal for apoptosis.
14 Therefore, DISC formation was assessed in 786-O cells treated with HDACi or vehicles and then stimulated with recombinant TRAIL for 1 h. As shown in Figure 1e , there was clearly more TRAIL-R2 immunoprecipitated from the HDACi-treated cells compared to vehicle-treated cells. The doublet observed in the blot with the anti-TRAIL-R2 mAb is consistent with previous observations predicting two variants of TRAIL-R2, resulting from an 11 amino-acid deletion at the amino terminus. 15 In addition, dramatically increased amounts of FADD were co-precipitated with the TRAIL-R2. These results demonstrate that TRAIL receptor DISC assembly was accelerated in the HDACitreated cells, which can account for the increased tumor cell death. To further determine the effects of enhanced DISC formation, the activation status of caspase-8 was measured. As expected, caspase-8 activity was increased in HDACi-treated Ad5-TRAIL-infected 786-O cells (Figure 1f) . Collectively, these data show that HDAC inhibition of the TRAIL-resistant 786-O cell line increases cell sensitivity to Ad5-TRAIL infection, permits heightened expression of the Ad5-TRAIL transgene and induces the expression of TRAIL-R2. All of these processes result in a stronger apoptotic signal and greater tumor cell death. In contrast, normal RPTEC do not display any increase in TRAIL receptor expression, caspase-8 activation or cell death when treated with the combination of HDACi (except trichostatin A) and Ad5-TRAIL.
Carcinogenesis commonly occurs as a result of the repression of tumor suppressor genes. One mechanism that helps to regulate gene expression is the differential acetylation of nucleosomal histone proteins that alter chromatin conformation and, consequently, activate or repress transcription. 16 The notion of using HDACi to treat cancer largely stems from the fact that HDACi maintain chromatin in a hyperacetylated state, leading to the expression of repressed genes that result in growth arrest, terminal differentiation and/or cell death of the tumor cell. 8, 17 More recently, it was found that HDAC inhibition alters cell sensitivity to adenoviral infection, 11, 18 opening the way for combination therapy studies with recombinant adenoviral vectors designed to induce tumor cell death. In this study, we examined the ability of five different HDACi to alter renal cancer cell sensitivity to Ad5-TRAIL-mediated apoptosis. Our results demonstrate that the normally TRAIL-resistant RCC cell line 786-O can be effectively killed by Ad5-TRAIL after HDACi treatment, and the increased tumor cell death correlates with HDACi-induced increase in adenoviral infectivity, adenoviral transgene expression, TRAIL-R2 expression and TRAIL receptor DISC assembly.
The HDACi utilized in this study come from different classes, but they were all able to facilitate histone hyperacetylation in 786-O cells (data not shown). The similarities among the inhibitors ended there, and the differences in their abilities to augment adenoviral infection, transgene expression and TRAIL/Apo-2L-induced death became evident. Within the system we described, depsipeptide consistently showed the weakest ability to augment adenoviral infection or transgene expression, whereas trichostatin A was the strongest. It remains unknown why this occurred, but it is possible that HDACs targeted by the different inhibitors are different, resulting in the reported differences. It is possible that each inhibitor, depending on the HDACs they inhibit, allows for altered gene expression that is unique to certain HDACi, although there is some overlap with other genes that are upregulated by a variety of HDACi.
The success of Ad5-TRAIL, as with any adenoviral vector, is dependent on CAR expression on the target cell of interest. Despite being widely expressed on most normal epithelial cells, CAR levels can be variable on different tumor cell lines of the same tissue origin. 19 We initially became interested in the combination of HDACi and Ad5-TRAIL because of the ability of HDACi to induce CAR expression. Surprisingly, though, there has been limited investigation into the combination of HDACi and recombinant adenoviral vectors designed for gene transfer-based therapies. Our studies are unique in that we have combined two agents that complement each other to produce a superior outcome compared to either agent individually. It must also remain evident that the results we obtained are likely to be tumor cell-specific, and the combination of HDACi and Ad5-TRAIL may have different outcomes with other tumor cell types.
